Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy

BackgroundAntiretroviral therapy is associated with adverse events (AEs). The most frequently reported AE associated with lopinavir/ritonavir (LPV/r) containing regimens is diarrhea. The objective of this meta-analysis is to describe the incidence, prevalence, and duration of diarrhea in individuals...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International Association of Providers of AIDS Care 2012-08, Vol.11 (4), p.252-259
Main Authors: Wegzyn, Colleen M, Fredrick, Linda M, Stubbs, Roxann O, Woodward, William C, Norton, Michael
Format: Article
Language:English
Subjects:
Antiretroviral drugs
Antiretroviral therapy
Antiviral drugs
Clinical trials
Diarrhea
Meta-analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1174-ac016b3d798aaf1a1921c3e339e0ce3f78aab16ba016485fe4035d4b756542f3
cites
container_end_page 259
container_issue 4
container_start_page 252
container_title Journal of the International Association of Providers of AIDS Care
container_volume 11
creator Wegzyn, Colleen M
Fredrick, Linda M
Stubbs, Roxann O
Woodward, William C
Norton, Michael
description BackgroundAntiretroviral therapy is associated with adverse events (AEs). The most frequently reported AE associated with lopinavir/ritonavir (LPV/r) containing regimens is diarrhea. The objective of this meta-analysis is to describe the incidence, prevalence, and duration of diarrhea in individuals taking LPV/r.MethodsThis is a meta-analysis of Abbott-conducted clinical trials. Inclusion criteria included prospective randomized clinical trials with the LPV/r tablet formulation and had AE data (moderate/severe diarrhea) available through 48 weeks of treatment.ResultsThree trials (total 1469 participants) met the inclusion criteria. In all, 11.2% of participants reported moderate/severe diarrhea by week 8, with median time to resolution of 7.4 weeks. The overall 48-week incidence of moderate/severe diarrhea was 15.5%. The discontinuation rate due to moderate/severe diarrhea was 1.3%.ConclusionsModerate/severe diarrhea occurred in less than 1 in 6 participants taking LPV/r, typically started in the first 8 weeks of treatment and infrequently resulted in premature discontinuation.
doi_str_mv 10.1177/1545109712442984
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2343476448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2343476448</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1174-ac016b3d798aaf1a1921c3e339e0ce3f78aab16ba016485fe4035d4b756542f3</originalsourceid><addsrcrecordid>eNo9js1LxDAQxYMouKx791jwHDfJTJrE27p-QkGQ3pdpm9Issq1JV_G_N6g4l_nx5vHeMHYpxbWUxqylRi2FM1IhKmfxhC0UKM2dtur0nw2es1VKe5HHqlJYs2A3d4FiHDwVm5TGNtDsu-IzzENRjVM40EeI69cwjz_Ebynlcz34SNPXBTvr6S351d9esvrhvt4-8erl8Xm7qXibf0NOrZBlA51xlqiXJJ2SLXgA50XroTdZbrKDsg2t7j0K0B02RpcaVQ9LdvUbO8Xx_ejTvNuPx3jIjTsFCGhKRAvfKbVJCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2343476448</pqid></control><display><type>article</type><title>Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy</title><source>Publicly Available Content Database</source><source>Sociological Abstracts</source><creator>Wegzyn, Colleen M ; Fredrick, Linda M ; Stubbs, Roxann O ; Woodward, William C ; Norton, Michael</creator><creatorcontrib>Wegzyn, Colleen M ; Fredrick, Linda M ; Stubbs, Roxann O ; Woodward, William C ; Norton, Michael</creatorcontrib><description>BackgroundAntiretroviral therapy is associated with adverse events (AEs). The most frequently reported AE associated with lopinavir/ritonavir (LPV/r) containing regimens is diarrhea. The objective of this meta-analysis is to describe the incidence, prevalence, and duration of diarrhea in individuals taking LPV/r.MethodsThis is a meta-analysis of Abbott-conducted clinical trials. Inclusion criteria included prospective randomized clinical trials with the LPV/r tablet formulation and had AE data (moderate/severe diarrhea) available through 48 weeks of treatment.ResultsThree trials (total 1469 participants) met the inclusion criteria. In all, 11.2% of participants reported moderate/severe diarrhea by week 8, with median time to resolution of 7.4 weeks. The overall 48-week incidence of moderate/severe diarrhea was 15.5%. The discontinuation rate due to moderate/severe diarrhea was 1.3%.ConclusionsModerate/severe diarrhea occurred in less than 1 in 6 participants taking LPV/r, typically started in the first 8 weeks of treatment and infrequently resulted in premature discontinuation.</description><identifier>ISSN: 2325-9574</identifier><identifier>EISSN: 2325-9582</identifier><identifier>DOI: 10.1177/1545109712442984</identifier><language>eng</language><publisher>Thousand Oaks: SAGE PUBLICATIONS, INC</publisher><subject>Antiretroviral drugs ; Antiretroviral therapy ; Antiviral drugs ; Clinical trials ; Diarrhea ; Meta-analysis</subject><ispartof>Journal of the International Association of Providers of AIDS Care, 2012-08, Vol.11 (4), p.252-259</ispartof><rights>The Author(s) 2012. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1174-ac016b3d798aaf1a1921c3e339e0ce3f78aab16ba016485fe4035d4b756542f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2343476448?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25752,27343,27923,27924,33773,37011,44589</link.rule.ids></links><search><creatorcontrib>Wegzyn, Colleen M</creatorcontrib><creatorcontrib>Fredrick, Linda M</creatorcontrib><creatorcontrib>Stubbs, Roxann O</creatorcontrib><creatorcontrib>Woodward, William C</creatorcontrib><creatorcontrib>Norton, Michael</creatorcontrib><title>Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy</title><title>Journal of the International Association of Providers of AIDS Care</title><description>BackgroundAntiretroviral therapy is associated with adverse events (AEs). The most frequently reported AE associated with lopinavir/ritonavir (LPV/r) containing regimens is diarrhea. The objective of this meta-analysis is to describe the incidence, prevalence, and duration of diarrhea in individuals taking LPV/r.MethodsThis is a meta-analysis of Abbott-conducted clinical trials. Inclusion criteria included prospective randomized clinical trials with the LPV/r tablet formulation and had AE data (moderate/severe diarrhea) available through 48 weeks of treatment.ResultsThree trials (total 1469 participants) met the inclusion criteria. In all, 11.2% of participants reported moderate/severe diarrhea by week 8, with median time to resolution of 7.4 weeks. The overall 48-week incidence of moderate/severe diarrhea was 15.5%. The discontinuation rate due to moderate/severe diarrhea was 1.3%.ConclusionsModerate/severe diarrhea occurred in less than 1 in 6 participants taking LPV/r, typically started in the first 8 weeks of treatment and infrequently resulted in premature discontinuation.</description><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Antiviral drugs</subject><subject>Clinical trials</subject><subject>Diarrhea</subject><subject>Meta-analysis</subject><issn>2325-9574</issn><issn>2325-9582</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>BHHNA</sourceid><sourceid>PIMPY</sourceid><recordid>eNo9js1LxDAQxYMouKx791jwHDfJTJrE27p-QkGQ3pdpm9Issq1JV_G_N6g4l_nx5vHeMHYpxbWUxqylRi2FM1IhKmfxhC0UKM2dtur0nw2es1VKe5HHqlJYs2A3d4FiHDwVm5TGNtDsu-IzzENRjVM40EeI69cwjz_Ebynlcz34SNPXBTvr6S351d9esvrhvt4-8erl8Xm7qXibf0NOrZBlA51xlqiXJJ2SLXgA50XroTdZbrKDsg2t7j0K0B02RpcaVQ9LdvUbO8Xx_ejTvNuPx3jIjTsFCGhKRAvfKbVJCA</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Wegzyn, Colleen M</creator><creator>Fredrick, Linda M</creator><creator>Stubbs, Roxann O</creator><creator>Woodward, William C</creator><creator>Norton, Michael</creator><general>SAGE PUBLICATIONS, INC</general><scope>3V.</scope><scope>7U3</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHHNA</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20120801</creationdate><title>Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy</title><author>Wegzyn, Colleen M ; Fredrick, Linda M ; Stubbs, Roxann O ; Woodward, William C ; Norton, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1174-ac016b3d798aaf1a1921c3e339e0ce3f78aab16ba016485fe4035d4b756542f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Antiviral drugs</topic><topic>Clinical trials</topic><topic>Diarrhea</topic><topic>Meta-analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wegzyn, Colleen M</creatorcontrib><creatorcontrib>Fredrick, Linda M</creatorcontrib><creatorcontrib>Stubbs, Roxann O</creatorcontrib><creatorcontrib>Woodward, William C</creatorcontrib><creatorcontrib>Norton, Michael</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Social Services Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Sociological Abstracts</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of the International Association of Providers of AIDS Care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wegzyn, Colleen M</au><au>Fredrick, Linda M</au><au>Stubbs, Roxann O</au><au>Woodward, William C</au><au>Norton, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy</atitle><jtitle>Journal of the International Association of Providers of AIDS Care</jtitle><date>2012-08-01</date><risdate>2012</risdate><volume>11</volume><issue>4</issue><spage>252</spage><epage>259</epage><pages>252-259</pages><issn>2325-9574</issn><eissn>2325-9582</eissn><abstract>BackgroundAntiretroviral therapy is associated with adverse events (AEs). The most frequently reported AE associated with lopinavir/ritonavir (LPV/r) containing regimens is diarrhea. The objective of this meta-analysis is to describe the incidence, prevalence, and duration of diarrhea in individuals taking LPV/r.MethodsThis is a meta-analysis of Abbott-conducted clinical trials. Inclusion criteria included prospective randomized clinical trials with the LPV/r tablet formulation and had AE data (moderate/severe diarrhea) available through 48 weeks of treatment.ResultsThree trials (total 1469 participants) met the inclusion criteria. In all, 11.2% of participants reported moderate/severe diarrhea by week 8, with median time to resolution of 7.4 weeks. The overall 48-week incidence of moderate/severe diarrhea was 15.5%. The discontinuation rate due to moderate/severe diarrhea was 1.3%.ConclusionsModerate/severe diarrhea occurred in less than 1 in 6 participants taking LPV/r, typically started in the first 8 weeks of treatment and infrequently resulted in premature discontinuation.</abstract><cop>Thousand Oaks</cop><pub>SAGE PUBLICATIONS, INC</pub><doi>10.1177/1545109712442984</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2325-9574
ispartof Journal of the International Association of Providers of AIDS Care, 2012-08, Vol.11 (4), p.252-259
issn 2325-9574
2325-9582
language eng
recordid cdi_proquest_journals_2343476448
source Publicly Available Content Database; Sociological Abstracts
subjects Antiretroviral drugs
Antiretroviral therapy
Antiviral drugs
Clinical trials
Diarrhea
Meta-analysis
title Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A40%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diarrhea%20Associated%20with%20Lopinavir/Ritonavir-Based%20Therapy&rft.jtitle=Journal%20of%20the%20International%20Association%20of%20Providers%20of%20AIDS%20Care&rft.au=Wegzyn,%20Colleen%20M&rft.date=2012-08-01&rft.volume=11&rft.issue=4&rft.spage=252&rft.epage=259&rft.pages=252-259&rft.issn=2325-9574&rft.eissn=2325-9582&rft_id=info:doi/10.1177/1545109712442984&rft_dat=%3Cproquest%3E2343476448%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1174-ac016b3d798aaf1a1921c3e339e0ce3f78aab16ba016485fe4035d4b756542f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2343476448&rft_id=info:pmid/&rfr_iscdi=true